Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors

开发 7HP349,一种口服整合素激活剂,可增强对免疫检查点抑制剂的治疗反应

基本信息

  • 批准号:
    10261525
  • 负责人:
  • 金额:
    $ 101.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-11 至 2022-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Immune checkpoint inhibitors (CPIs), such aPD-1 agents (nivolumab, and pembrolizumab), are the current standard of care treatment for the frontline management of advanced melanoma and other solid tumors. However, ~70% of patients with approved FDA indications do not respond. Importantly, once patients progress, there are limited treatment options. Primary and acquired resistance to checkpoint inhibitors may be due to the lack of immune effector cell priming and trafficking into tumor tissue. 7HP349 is a first-in-concept, oral, small molecule, positive allosteric activator of specific integrin cell adhesion molecules, VLA-4 and LFA-1, which are essential for generation of a cellular immune response against solid tumors. These integrins are critical for T cell priming and tumor infiltration, and have been shown necessary for the effectiveness of immune checkpoint inhibitors, as well as for T cell vaccines. 7HP349, as systemic drug, has shown enhancement of spontaneous anti-tumor immunity alone or in combination with CPIs. Based on its favorable preclinical profile, US Food and Drug Administration, Division of Oncology Products 3, has approved the 7HP349 IND to conduct the proposed Phase 1 first-in-human study to lay the foundation for future studies in cancer patients. cGMP drug substance and drug product have been developed for first-in-human studies. In this Direct to Phase II grant, we plan to assess the safety and tolerability, and determine the 7HP349 optimal pharmacokinetic dose (OPD) and optimal biologic dose (OBD) for improving immune checkpoint blockade by performing the first-in-human study in healthy volunteers. This proposed Phase I study will not only guide the future evaluation of 7HP349 to augment antigen presentation in solid tumor patients that have failed PD-1- based therapies for potential approval in refractory melanoma, but also lay the foundation for the potential use in increasing the effectiveness of infectious disease vaccines.
项目总结/摘要 免疫检查点抑制剂(CPI),如aPD-1药物(纳武单抗和派姆单抗),是目前的治疗药物。 晚期黑色素瘤和其他实体瘤一线治疗的标准治疗。 然而,约70%具有FDA批准适应症的患者没有反应。重要的是,一旦患者 进展,治疗选择有限。对检查点抑制剂的原发性和获得性耐药性可能是 这是由于缺乏免疫效应细胞引发和运输到肿瘤组织中。7 HP 349是第一个概念, 口服,小分子,特异性整联蛋白细胞粘附分子的正变构激活剂,VLA-4和LFA-1, 其对于产生针对实体瘤的细胞免疫应答是必需的。这些整合素是 对于T细胞引发和肿瘤浸润至关重要,并且已经显示对于 免疫检查点抑制剂,以及T细胞疫苗。7 HP 349作为全身用药, 单独或与CPI组合增强自发抗肿瘤免疫。基于其良好的 临床前概况,美国食品药品监督管理局肿瘤产品3部已批准 7 HP 349 IND进行拟议的I期首次人体研究,为未来的研究奠定基础。 癌症患者。cGMP原料药和制剂已开发用于首次人体研究。在 我们计划评估7 HP 349的安全性和耐受性,并确定7 HP 349的最佳治疗方案。 用于改善免疫检查点阻断的药代动力学剂量(OPD)和最佳生物剂量(OBD) 在健康志愿者中进行首次人体研究。这项拟议的第一阶段研究不仅将指导 未来评估7 HP 349在PD-1失败的实体瘤患者中增强抗原呈递的作用- 为潜在的难治性黑色素瘤批准的基础疗法,也奠定了潜在的使用基础 提高传染病疫苗的有效性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LIONEL David LEWIS其他文献

LIONEL David LEWIS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LIONEL David LEWIS', 18)}}的其他基金

7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
7HP349,一种整合素激活剂,用于治疗抗 PD-1 耐药实体瘤患者
  • 批准号:
    10761171
  • 财政年份:
    2023
  • 资助金额:
    $ 101.56万
  • 项目类别:
Toxicology, Pathology and Biodistribution Core (TPB Core)
毒理学、病理学和生物分布核心(TPB 核心)
  • 批准号:
    7982610
  • 财政年份:
    2010
  • 资助金额:
    $ 101.56万
  • 项目类别:
CLINICAL PHARMACOLOGY SHARED RESOURCE
临床药理学共享资源
  • 批准号:
    7944619
  • 财政年份:
    2009
  • 资助金额:
    $ 101.56万
  • 项目类别:
PROTOCOL REVIEW AND MONITORING SYSTEM
方案审查和监测系统
  • 批准号:
    7944683
  • 财政年份:
    2009
  • 资助金额:
    $ 101.56万
  • 项目类别:
Clinical Molecular
临床分子
  • 批准号:
    6989452
  • 财政年份:
    2004
  • 资助金额:
    $ 101.56万
  • 项目类别:
Clinical Pharmacology (CP)
临床药理学(CP)
  • 批准号:
    10554245
  • 财政年份:
    1997
  • 资助金额:
    $ 101.56万
  • 项目类别:
Clinical Pharmacology (CP)
临床药理学(CP)
  • 批准号:
    8804008
  • 财政年份:
    1997
  • 资助金额:
    $ 101.56万
  • 项目类别:
Clinical Pharmacology (CP)
临床药理学(CP)
  • 批准号:
    10311226
  • 财政年份:
    1997
  • 资助金额:
    $ 101.56万
  • 项目类别:
Protocol Review and Monitoring System (PRMS)
方案审查和监控系统 (PRMS)
  • 批准号:
    10554303
  • 财政年份:
    1997
  • 资助金额:
    $ 101.56万
  • 项目类别:
Protocol Review and Monitoring System (PRMS)
方案审查和监控系统 (PRMS)
  • 批准号:
    10311241
  • 财政年份:
    1997
  • 资助金额:
    $ 101.56万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 101.56万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 101.56万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 101.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 101.56万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 101.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 101.56万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 101.56万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 101.56万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 101.56万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 101.56万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了